PURPOSE: Nitric oxide (NO) may control intraocular pressure (IOP)-regulating mechanisms physiologically and in ocular diseases such as glaucoma. The aim of the present study was to clarify whether an increase in aqueous humor outflow facility could explain the IOP-lowering effect of the NO/cyclic GMP pathway we recently described. METHODS: Test compounds were administered to anesthetized rabbits (New Zealand White, n = 6) intracamerally (5 microl) in the following doses: nitrosocaptopril 12.3 microg, captopril 10.9 microg, sodium nitroprusside (SNP) 13.1 microg and 8-Br-cGMP 22.3 microg. Outflow facility (C) was determined by the two-level constant pressure infusion method. Outflow facility, C( 1) and C(2), was measured at lower and higher pressure levels, respectively. RESULTS: Outflow facility was increased after treatment with SNP (increase in C in the experimental eye as compared to the control eye C( 1) 80% and C(2) 74%), nitrosocaptopril (C(1) 69% and C(2) 64%) and 8-Br-cGMP (C(1) 35% and C(2) 33%). Captopril had no effect on outflow facility (C(1) -12% and C(2) 2%). Blood pressure was not affected by the drugs. CONCLUSIONS: We conclude that enhancement of outflow facility by nitrosocaptopril, SNP and 8-Br-cGMP, their second messenger derivative, at least partly explains the IOP-lowering effect of NO releasing compounds.
PURPOSE:Nitric oxide (NO) may control intraocular pressure (IOP)-regulating mechanisms physiologically and in ocular diseases such as glaucoma. The aim of the present study was to clarify whether an increase in aqueous humor outflow facility could explain the IOP-lowering effect of the NO/cyclic GMP pathway we recently described. METHODS: Test compounds were administered to anesthetized rabbits (New Zealand White, n = 6) intracamerally (5 microl) in the following doses: nitrosocaptopril 12.3 microg, captopril 10.9 microg, sodium nitroprusside (SNP) 13.1 microg and 8-Br-cGMP 22.3 microg. Outflow facility (C) was determined by the two-level constant pressure infusion method. Outflow facility, C( 1) and C(2), was measured at lower and higher pressure levels, respectively. RESULTS: Outflow facility was increased after treatment with SNP (increase in C in the experimental eye as compared to the control eye C( 1) 80% and C(2) 74%), nitrosocaptopril (C(1) 69% and C(2) 64%) and 8-Br-cGMP (C(1) 35% and C(2) 33%). Captopril had no effect on outflow facility (C(1) -12% and C(2) 2%). Blood pressure was not affected by the drugs. CONCLUSIONS: We conclude that enhancement of outflow facility by nitrosocaptopril, SNP and 8-Br-cGMP, their second messenger derivative, at least partly explains the IOP-lowering effect of NO releasing compounds.
Authors: Joshua D Stein; Paula Anne Newman-Casey; Nidhi Talwar; Bin Nan; Julia E Richards; David C Musch Journal: Ophthalmology Date: 2012-06-21 Impact factor: 12.079
Authors: Lauren K Wareham; Ana C Dordea; Grigorij Schleifer; Vincent Yao; Annabelle Batten; Fei Fei; Joseph Mertz; Meredith Gregory-Ksander; Louis R Pasquale; Emmanuel S Buys; Rebecca M Sappington Journal: Neurobiol Dis Date: 2018-09-10 Impact factor: 5.996
Authors: Jason Y H Chang; W Daniel Stamer; Jacques Bertrand; A Thomas Read; Catherine M Marando; C Ross Ethier; Darryl R Overby Journal: Am J Physiol Cell Physiol Date: 2015-06-03 Impact factor: 4.249
Authors: W Daniel Stamer; Yuan Lei; Alexandra Boussommier-Calleja; Darryl R Overby; C Ross Ethier Journal: Invest Ophthalmol Vis Sci Date: 2011-12-09 Impact factor: 4.799
Authors: James T Lane; Luann Larson; Shan Fan; Julie A Stoner; Eyal Margalit; Carol B Toris Journal: BMC Ophthalmol Date: 2010-06-23 Impact factor: 2.209